Real-world experience with mild-moderate COVID-19 therapies in kidney transplant patients: How to treat patients with chronic kidney disease from now on?

Nefrologia (Engl Ed). 2024 May-Jun;44(3):433-435. doi: 10.1016/j.nefroe.2024.06.003. Epub 2024 Jun 25.

Affiliations

¹ Servicio de Nefrología, Hospital Universitario Puerta del Mar, Cádiz, Spain.
² Servicio de Farmacia Hospitalaria, Hospital Universitario Puerta del Mar, Cádiz, Spain.
³ Servicio de Nefrología, Hospital Universitario de Jerez, Cádiz, Spain.
⁴ Servicio de Nefrología, Hospital Universitario Puerta del Mar, Cádiz, Spain. Electronic address: [email protected].

PMID: 38918164
DOI: 10.1016/j.nefroe.2024.06.003

No abstract available

Publication types

Letter

MeSH terms

Aged
Antiviral Agents / therapeutic use
COVID-19 Drug Treatment
COVID-19* / complications
Female
Humans
Kidney Transplantation*
Male
Middle Aged
Renal Insufficiency, Chronic* / complications
SARS-CoV-2
Severity of Illness Index

Substances

Antiviral Agents